ShangPharma Corporation, the second-largest Chinese pharmaceutical/biotechnology R&D outsourcing firm, will see its quiet period end on Saturday, November 27. On October 18, the company raised $87 million by offering 5.8 million ADSs at $15, within the range of...read more
ShangPharma Corporation, the second-largest Chinese pharmaceutical/biotechnology R&D outsourcing firm, raised $87 million by offering 5.8 million ADSs at $15, within the range of $14.50-$16.50. ShangPharma Corporation plans to list on the NYSE under the symbol...read more
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology R&D outsourcing company, filed and announced terms for its IPO on Thursday. The Shanghai-based company plans to raise $90 million by offering 5.8 million ADSs at a price range of...read more
ShangPharma quiet period ends November 27
ShangPharma Corporation, the second-largest Chinese pharmaceutical/biotechnology R&D outsourcing firm, will see its quiet period end on Saturday, November 27. On October 18, the company raised $87 million by offering 5.8 million ADSs at $15, within the range of...read more
ShangPharma prices IPO at $15, within the range
ShangPharma Corporation, the second-largest Chinese pharmaceutical/biotechnology R&D outsourcing firm, raised $87 million by offering 5.8 million ADSs at $15, within the range of $14.50-$16.50. ShangPharma Corporation plans to list on the NYSE under the symbol...read more
6 IPOs planned for the week of Oct 18
The following IPOs are expected to price this week:
Aegerion Pharmaceuticals (AEGR), which is developing a drug for an orphan disease that produces fatal levels of...read more
China-based R&D company ShangPharma Corporation plans $90 million IPO
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology R&D outsourcing company, filed and announced terms for its IPO on Thursday. The Shanghai-based company plans to raise $90 million by offering 5.8 million ADSs at a price range of...read more